Homocysteine induces cardiomyocyte dysfunction and apoptosis through p38 MAPK-mediated increase in oxidant stress

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 753-760

  Wang, Xu ^a,b   Cui, Lei ^b   Joseph, Jacob ^a,c   Jiang, Bingbing ^a   Pimental, David ^b   Handy, Diane E ^a   Liao, Ronglih ^a   Loscalzo, Joseph ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Antioxidant; Apoptosis; Cardiomyocytes; Contractility; Homocysteine; Hyperhomocysteinemia; Ischemia reperfusion injury; Oxidative stress

Indexed keywords

CASPASE 3; CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; THIOREDOXIN;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL FUNCTION; CELL STRESS; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HETEROZYGOTE; HYPERHOMOCYSTEINEMIA; IMMUNOBLOTTING; IN VITRO STUDY; ISOLATED HEART; MYOCARDIAL DISEASE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; WILD TYPE;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; THIOREDOXINS;

ADENOVIRIDAE; MUS; RATTUS;

EID: 84862809910     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.12.009     Document Type: Article

References (48)

1. Mudd S.H., Finkelstein J.D., Refsum H., et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000, 20:1704-1706.
2. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
3. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
4. Cheng S.W., Ting A.C., Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997, 11:217-223.
5. den Heijer M., Koster T., Blom H.J., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996, 334:759-762.
6. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
7. Parnetti L., Caso V., Santucci A., et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 2004, 25:13-17.
8. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
9. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006, 354:1629-1632.
10. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
11. Durand P., Prost M., Loreau N., et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001, 81:645-672.
12. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2074-2081.
13. Nygard O., Vollset S.E., Refsum H., et al. Total homocysteine and cardiovascular disease. J Intern Med 1999, 246:425-454.
14. Weiss N., Zhang Y.Y., Heydrick S., et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A 2001, 98:12503-12508.
15. Blacher J., Demuth K., Guerin A.P., et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999, 12:248-255.
16. Joseph J., Joseph L., Shekhawat N.S., et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003, 285:H679-H686.
17. Joseph J., Washington A., Joseph L., et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002, 283:H2567-H2574.
18. Becker J.S., Adler A., Schneeberger A., et al. Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation 2005, 111:2112-2118.
19. Suematsu N., Ojaimi C., Kinugawa S., et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 2007, 115:255-262.
20. Watanabe M., Osada J., Aratani Y., et al. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A 1995, 92:1585-1589.
21. Kontaridis M.I., Yang W., Bence K.K., et al. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation 2008, 117:1423-1435.
22. Jain M., Cui L., Brenner D.A., et al. Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation 2004, 109:898-903.
23. Jain M., Brenner D.A., Cui L., et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res 2003, 93:e9-e16.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
25. Liao P., Wang S.Q., Wang S., et al. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 2002, 90:190-196.
26. Kaiser R.A., Bueno O.F., Lips D.J., et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 2004, 279:15524-15530.
27. Yamamoto M., Yang G., Hong C., et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003, 112:1395-1406.
28. Bao L., Vlcek C., Paces V., Kraus J.P. Identification and tissue distribution of human cystathionine beta-synthase mRNA isoforms. Arch Biochem Biophys 1998, 350:95-103.
29. Chasse J.F., Paly E., Paris D., et al. Genomic organization of the human cystathionine beta-synthase gene: evidence for various cDNAs. Biochem Biophys Res Commun 1995, 211:826-832.
30. Chen P., Poddar R., Tipa E.V., et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 1999, 39:93-109.
31. Eberhardt R.T., Forgione M.A., Cap A., et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000, 106:483-491.
32. Handy D.E., Zhang Y., Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 2005, 280:15518-15525.
33. Vahebi S., Ota A., Li M., et al. p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res 2007, 100:408-415.
34. Gustafsson A.B., Gottlieb R.A. Mechanisms of apoptosis in the heart. J Clin Immunol 2003, 23:447-459.
35. Bae S., Yalamarti B., Kang P.M. Role of caspase-independent apoptosis in cardiovascular diseases. Front Biosci 2008, 13:2495-2503.
36. Sipkens J.A., Krijnen P.A., Meischl C., et al. Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis. Apoptosis 2007, 12:1407-1418.
37. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
38. Grandel U., Fink L., Blum A., et al. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 2000, 102:2758-2764.
39. von Harsdorf R., Li P.F., Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999, 99:2934-2941.
40. Levrand S., Pacher P., Pesse B., et al. Homocysteine induces cell death in H9C2 cardiomyocytes through the generation of peroxynitrite. Biochem Biophys Res Commun 2007, 359:445-450.
41. Petrich B.G., Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med 2004, 14:50-55.
42. Liao P., Georgakopoulos D., Kovacs A., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 2001, 98:12283-12288.
43. Kim K.M., Pae H.O., Zheng M., et al. Carbon monoxide induces heme oxygenase-1 via activation of protein kinase R-like endoplasmic reticulum kinase and inhibits endothelial cell apoptosis triggered by endoplasmic reticulum stress. Circ Res 2007, 101:919-927.
44. Leoncini G., Bruzzese D., Signorello M.G. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Haemost 2006, 4:209-216.
45. Akasaka K., Akasaka N., Di Luozzo G., et al. Homocysteine promotes p38-dependent chemotaxis in bovine aortic smooth muscle cells. J Vasc Surg 2005, 41:517-522.
46. McDermott E.P., O'Neill L.A. Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem 2002, 277:7808-7815.
47. Bertuglia S., Giusti A. Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am J Physiol Heart Circ Physiol 2003, 285:H1064-H1071.
48. Zweier J.L., Flaherty J.T., Weisfeldt M.L. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A 1987, 84:1404-1407.